|Bid||0.00 x 1100|
|Ask||0.00 x 1300|
|Day's Range||153.03 - 155.50|
|52 Week Range||118.10 - 165.14|
|Beta (3Y Monthly)||0.68|
|PE Ratio (TTM)||23.24|
|Earnings Date||Oct 23, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||168.92|
ICON plc, (ICLR) a global provider of drug and device development and commercialisation services to the pharmaceutical, biotechnology and medical device industries, today announced that Mr. Brendan Brennan, CFO of ICON plc, will present at Jefferies 2019 London Healthcare Conference on Thursday, November 21, 2019. ICON plc is a global provider of outsourced drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device and government and public health organisations.
When you buy a stock there is always a possibility that it could drop 100%. But on a lighter note, a good company can...
Icon PLC (ICLR) delivered earnings and revenue surprises of 0.58% and 0.32%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
ICON plc, (ICLR) a global provider of drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device industries, today announced that it has acquired Symphony Clinical Research, a leading provider of at-home patient and site support services. The acquisition, concluded in late September, further enhances ICON’s patient, site and data strategy and complements ICON’s existing PMG Research and MeDiNova Research site networks in the US and EMEA. Symphony’s services reduce the travel burden for patients which broadens ICON’s recruitable population, providing patients access to clinical research studies that they may not have otherwise been able to participate in.
Icon PLC (ICLR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
World-class money managers like Ken Griffin and Barry Rosenstein only invest their wealthy clients' money after undertaking a rigorous examination of any potential stock. They are particularly successful in this regard when it comes to small-cap stocks, which their peerless research gives them a big information advantage on when it comes to judging their worth. […]
The average healthcare stock in the S&P; 1500 Index has returned 8% including dividends this year, just below the broad index's average total return of 9%, explains Richard Moroney, editor of Dow Theory Forecasts.
This article is for investors who would like to improve their understanding of price to earnings ratios (P/E ratios...
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of ICON Plc and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers. This publication does not announce a credit rating action and is not an indication of whether or not a credit rating action is likely in the near future.
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...
Icon PLC (ICLR) delivered earnings and revenue surprises of 0.60% and 0.40%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?